据了解，迈瑞医疗与惠泰医疗的整合工作中，双方在业务、资产、人员、财务、机构等维度全面落 实"五独立"要求，这一安排从制度层面有效保障了两家上市公司的自主经营决策权。在此基础上，整合 需秉持互补协同原则而非全盘吸收合并的思路：让双方在各自擅长的领域充分发挥专业优势，在尊重惠 泰医疗现有业务格局的前提下，合力共赢，实现产业层面的价值协同。 研发突破引领增长 整体来看，医疗器械行业通过外延式并购实现发展已成为趋势。从行业底层逻辑来看，医疗器械领域具 有细分赛道多、技术壁垒高、注册监管严、产品周期长等显著特征。 深圳迈瑞生物医疗电子股份有限公司（以下简称"迈瑞医疗"）并购深圳惠泰医疗器械股份有限公司（以 下简称"惠泰医疗"）是科创板首单"A控A"并购交易，对中国医疗器械行业产业整合具有标志性意义。 从公告至完成过户仅历时3个月，成为大型医疗并购的高效范例。 近日，惠泰医疗董事长葛昊在接受《证券日报》记者专访时表示："并购落地后近19个月以来，双方在 研发、营销、业务拓展、运营等多个方面都开展了协同工作，其中电生理领域中的技术和产品协同更是 重中之重。对于公司未来的发展，可以说并购是起点，创新与全球化是未来。" 加快整 ...

Group 1: Market Expansion and Product Development - The company has shifted its medical glove exports away from the U.S., focusing on Europe, Japan, and emerging markets, achieving a market share of 20-30% in many regions [2] - The "Blue Sniper" series products, including the upgraded liquid mask, have maintained top sales positions on platforms like JD.com [3] - The company is expanding into minimally invasive surgery, neurointervention, and peripheral intervention, with several products already in the registration process [4][5] Group 2: Financial Performance - In 2024, the company reported a net cash flow from operating activities of 135,849,276.36 CNY, a year-on-year increase of 286.39% [6] - The total revenue for 2024 was 6,253,168,236.58 CNY, reflecting a growth of 26.91%, while the net loss narrowed by 21.60% [9] - In Q1 2025, revenue reached 1,477,911,477.13 CNY, a 1.59% increase, with a net profit of 77,022,348.52 CNY, up 177.86% [9] Group 3: Industry Trends and Future Outlook - The global cardiovascular intervention device market is projected to grow from 11.24 billion USD in 2024 to 15.53 billion USD by 2031, with a CAGR of 4.8% [12][15] - The global disposable glove market is expected to reach 8.293 billion units sold by 2025, with sales revenue projected at 13.6 billion USD [15] - The emergency rescue product market is anticipated to grow at a CAGR of 7.3% from 2025 to 2031, with a market value of 6.53 million USD in 2024 [13][16] Group 4: Strategic Initiatives - The company plans to enhance its health protection business by reducing reliance on the U.S. market and improving production efficiency [10] - A strategic investment of 1 billion CNY in the subsidiary Blue Fan Bo Sheng aims to boost R&D and production capacity [19] - The company is focusing on developing high-value products and optimizing cost structures to maximize shareholder value [11][19]